Next Article in Journal
Structure and Absolute Configuration of Phenanthro-perylene Quinone Pigments from the Deep-Sea Crinoid Hypalocrinus naresianus
Next Article in Special Issue
Synthesis of Marine Natural Products and Molecules Inspired by Marine Substances II
Previous Article in Journal
Sponges and Their Symbionts as a Source of Valuable Compounds in Cosmeceutical Field
Previous Article in Special Issue
Marine Alkaloids: Compounds with In Vivo Activity and Chemical Synthesis
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:

Recent Developments on the Synthesis and Bioactivity of Ilamycins/Rufomycins and Cyclomarins, Marine Cyclopeptides That Demonstrate Anti-Malaria and Anti-Tuberculosis Activity

Organic Chemistry, Saarland University, Campus Building C4.2, 66123 Saarbrücken, Germany
Helmholtz Institute for Pharmaceutical Research Saarland (HIPS)—Helmholtz Centre for Infection Research (HZI), Campus Building E8 1, 66123 Saarbrücken, Germany
Author to whom correspondence should be addressed.
Mar. Drugs 2021, 19(8), 446;
Received: 20 July 2021 / Revised: 29 July 2021 / Accepted: 30 July 2021 / Published: 3 August 2021


Ilamycins/rufomycins and cyclomarins are marine cycloheptapeptides containing unusual amino acids. Produced by Streptomyces sp., these compounds show potent activity against a range of mycobacteria, including multidrug-resistant strains of Mycobacterium tuberculosis. The cyclomarins are also very potent inhibitors of Plasmodium falciparum. Biosynthetically the cyclopeptides are obtained via a heptamodular nonribosomal peptide synthetase (NRPS) that directly incorporates some of the nonproteinogenic amino acids. A wide range of derivatives can be obtained by fermentation, while bioengineering also allows the mutasynthesis of derivatives, especially cyclomarins. Other derivatives are accessible by semisynthesis or total syntheses, reported for both natural product classes. The anti-tuberculosis (anti-TB) activity results from the binding of the peptides to the N-terminal domain (NTD) of the bacterial protease-associated unfoldase ClpC1, causing cell death by the uncontrolled proteolytic activity of this enzyme. Diadenosine triphosphate hydrolase (PfAp3Aase) was found to be the active target of the cyclomarins in Plasmodia. SAR studies with natural and synthetic derivatives on ilamycins/rufomycins and cyclomarins indicate which parts of the molecules can be simplified or otherwise modified without losing activity for either target. This review examines all aspects of the research conducted in the syntheses of these interesting cyclopeptides.

1. Introduction

Marine organisms produce a wealth of natural products, creating a universe of fascinating new chemical structures [1,2]. These natural products are often the result of an evolutionary process providing competitive advantages to their producers in their natural environments. Therefore, many of these natural products have notable biological activities, making them good candidates for drug development [3,4,5], including against infectious diseases such as malaria and tuberculosis.
Malaria is one of the most common tropical diseases, with more than 200 million infections and 600,000 deaths annually worldwide [6], mainly in the poorest population. Tuberculosis (TB) is also common: in 2019, approximately 10 million people fell ill with the disease and 1.5 million died [7]. In addition, in 2018, 500,000 people demonstrated resistance to rifampicin, the most effective first-line drug, 80% of whom suffer from multidrug-resistant tuberculosis (MDR-TB). The development of antibiotic resistance is widespread, and these multi-resistant pathogens are a particularly serious problem. Therefore, new drugs are required [8]. Most first- and second-line drugs were discovered or developed between 1940 and 1980, often with a similar mode of action, facilitating the development of resistance [9,10]. Modern drugs should therefore work via new modes of action against not only the MDR-TB strains but also the largely drug-resistant tuberculosis (XDR-TB) strains, which are now almost resistant to all drugs. In addition, any new drug should effectively destroy dormant bacteria, beneficial for short-term therapies, and be nontoxic (because of the generally long treatment times required). Natural products are excellent candidates for developing anti-TB drugs, and more than 60% of drugs under current development are natural products or derived from natural products [11,12,13].

2. Discovery of Anti-Tubercular Cycloheptapeptides

2.1. Discovery of the Ilamycins/Rufomycins

In 1962, two independent research groups investigated marine Streptomycetes from soil samples found on Japanese islands. Takita et al. observed that the culture filtrate of a new strain, Streptomyces insulates (A-165-Z1), later renamed Streptomyces islandicus, inhibited the growth of Mycobacterium 607 and Mycobacterium phlei. They isolated two antibiotics and named them ilamycin A and B (IlaA and IlaB) [14,15].
In addition, at this time Shibata et al. isolated two new antibiotics, rufomycin I and II (Ruf I and Ruf II), from the newly discovered Streptomyces atratus (46408), found to be especially active against acid-fast bacteria [16,17]. The compounds were also active against Mycobacterium tuberculosis and Mycobacterium smegmatis but almost inactive against most other bacteria, fungi, and yeasts. Subsequent research indicated that these two antibiotics possess very similar chemical structures [18,19,20,21,22,23].
The structures of ilamycins/rufomycins (Figure 1) are unusual, as these cyclic heptapeptides contain a series of atypical amino acids. Most prominent is the N-prenylated tryptophan ①, which can also be found in the epoxidized form [24,25]. At the N-terminus of the tryptophan, a γ,δ-unsaturated amino acid is incorporated ⑦ [26]. Common to all derivatives is a unique 3-nitrotyrosine ③, a building block not found in any other natural product. The greatest variability is observed in the leucine building block ⑤, which can be oxidized to different oxidation levels at a terminal methyl group. In its original description, ilamycin was proposed to contain an aldehyde functionality [23], but structural elucidation by NMR and X-ray crystallography showed that the aldehyde functionality undergoes cyclization with the nearby amide bond [27,28,29]. Very recently, a wide range of new ilamycins/rufomycins were described, differing mainly in the combination of different amino acid oxidation levels ⑤ and the N-prenyl substituent of ① (alkene, epoxide, diol) [27,28,29].

2.2. Discovery of the Cyclomarins

In 1999, the research groups of Fenical and Clardy reported the isolation of three new anti-inflammatory cyclic peptides from extracts of a Streptomyces sp. collected in Mission Bay, California [30]. These secondary metabolites from the strain CNB-982, called cyclomarins (Cym) A−C, are structurally related to the rufomycins. Very similar amino acid building blocks are incorporated, although in a different sequence. As in the rufomycins, an N-prenylated tryptophan ①(CymC) is a notable building block that can also be epoxidized (CymA). However, in contrast to the rufomycins, in the cyclomarin series, the tryptophan units are β-hydroxylated. At the N-terminus of the tryptophan, a γ,δ-unsaturated amino acid is incorporated, not a linear one as found in the rufomycins, but one that is branched and dimethylated ⑦. One of the leucines is also oxidized at the δ position ②, at least in CymA and C, but at another position, as in the rufomycins. Most obvious is the replacement of the unique nitrotyrosine by another aromatic amino acid, syn-β-methoxyphenylalanine ④.
In 2010, the group of Mikami described the extraction of a new cyclomarin derivative M10709 from clinically isolated Streptomyces sp. IFM 10,709 [31]. Although not all stereogenic centers were determined properly, results revealed the compound was different from cyclomarin C only by the replacement of the unsaturated amino acid ⑦ by valine. The same structural motif was also found in a recently isolated metamarine in which a valine at position ③ replaced an alanine. The discovery of metamarine resulted from a larger soil metagenome project undertaken to discover rufomycin/cyclomarin-like antibiotics [32].

3. Biosynthesis of Anti-Tubercular Cycloheptapeptides

Although the ilamycins/rufomycins were originally described in the early 1960s, biosynthetic studies of these unusual cyclopeptides were reported only recently [27,33]. The first investigations of cyclomarins were conducted in 2008 by the Moore group [34,35], while Brady et al. reported their results on metamarine biosynthesis in 2021 [32].
Although there are significant differences in the structures of these cycloheptapeptides, they also have structural similarities and common biosynthetic features (Figure 2). A key feature of the biosynthetic gene cluster is a gene encoding a heptamodular nonribosomal peptide synthetase (NRPS). This NRPS is surrounded by a set of open reading frames (ORF) that encodes tailoring enzymes (P450, oxygenases) and provides the required building blocks for peptide synthesis. They contain the unusual amino acids N-prenyl-tryptophan (p-Trp), 3-nitrotyrosine (Nitro-Tyr, ilamycins), as well as the unsaturated amino acids (2S,4E)-2-amino-4-hexenoic acid (AHA, ilamycins) and (2S,3R)-2-amino-3,5-dimethylhexenoic acid (ADH, cyclomarins). These building blocks are directly incorporated into the NRPS, while oxidative tailoring enzymes encoded in the ORFs modify the protein-bound peptide during synthesis. All biosyntheses start with the p-Trp ① and end with a cyclization between ① and the C-terminal amino acids ⑦.

3.1. Biosynthesis of the Ilamycins/Rufomycins

A total of 20 genes are involved in the biosynthesis of these cyclopeptides (Figure 2a) [27,36]. Besides the gene encoding the NRPS, a second large gene encodes a type I polyketide synthase (PKS), which is involved in AHA synthesis. (E)-4-Hexenic acid is obtained from AcCoA, and is further hydroxylated, oxidized (P450), and transaminated to AHA [33]. An N-prenyltransferase is responsible for the generation of the first amino acid of the sequence from tryptophan. The unusual 3-nitrotyrosine is obtained by P450-catalyzed nitrosation of tyrosine, and the NO required is provided by a nitric acid synthase from arginine [33]. Additional P450 cytochrome controls the final oxidation steps to create the different ilamycin family members [27].

3.2. Biosynthesis of Cyclomarins

Although the cyclomarins are structurally related to the ilamycins, they are significantly different, at least from a biosynthetic point of view (Figure 2b) [34,35]. In contrast to the ilamycins, the linear unsaturated amino acid AHA is replaced by the dimethylated derivative ADH, which has a completely different biosynthetic origin. While AHA is obtained by a classical polyketide synthase, ADH is formed from valine and pyruvate [35]. Of the 23 ORFs of the biosynthetic gene cluster, several genes are responsible for ADH synthesis. Another significant difference is the β-OH functionality of the prenylated tryptophan (p-Trp), which is found in all cyclomarins but not in the ilamycins and rufomycins. Its introduction is catalyzed by a tryptophan-β-hydroxylase, a dioxygenase, and occurs on the protein-bound peptide in the early stages of the biosynthesis. In contrast, epoxidation of the N-prenyl side chain by a P450 epoxidase occurs post-NRPS assembly. Gene inactivation of the prenyltransferase eliminated the production of cyclomarin, indicating that p-Trp is the initiator of the peptide assembly line and that the unmodified p-Trp is not a good substrate for the first acceptor domain [34]. The β-hydroxylation must occur during the first two steps of the peptide synthesis, since inactivation of the corresponding gene does not result in the formation of a desoxycyclomarin but the formation of a dioxopiperazine called cyclomarazine (Figure 3), containing only the first two amino acids of the biosynthesis.
CymA and CymB were isolated from the Streptomyces sp. CNB-982, together with CymD that was missing the N-methyl group on the δ-hydroxyleucine ②. It is clear that δ-hydroxylation by P450 leucine hydroxylase occurs faster than N-methylation, and tryptophan hydroxylation is essential for prolonging the peptide chain. If this hydroxylation does not occur properly, the incompletely processed dipeptide is cleaved from the NRPS due to ineffective processing by the next module. This reaction is a unique example in which a megasynthetase can produce two different natural products of different sizes simply by triggering the level of β-oxidation on the priming Trp unit. Notably, cyclomarazines do not show significant biological activity.
The second major way in which cyclomarins differ from ilamycins is the incorporation of β-methoxyphenylalanine (MeOPhe) instead of nitrotyrosine. This amino acid is obtained from a peptide-bound Phe via a P450-catalyzed β-hydroxylation followed by O-methylation [35].
During their soil metagenome project, Brady et al. also investigated the biosynthesis of metamarin. In this cyclomarin derivative, the unsaturated amino acid is replaced by valine (Figure 2c) [32]. Another valine is incorporated instead of alanine ③. Therefore, it is not surprising that the gene cluster is comparable to the cyclomarin cluster, and only the genes responsible for ADH biosynthesis are missing.

4. Total Syntheses of Marine Cycloheptapeptides

The interesting biological properties and unusual building blocks of marine cycloheptapeptides sparked the interest of synthetic chemists, and the syntheses of several different amino acids and fragments have been reported in a recent review [37]. Therefore, they will not be discussed in detail here, and the focus will be on the total syntheses of the natural products.

4.1. Total Synthesis of Ilamycins/Rufomycins

To date, only one synthetic route has been described for ilamycins E1 and F by Guo and Ye et al. [38]. In their highly convergent strategy, the ilamycins were synthesized from two parts (1 and 2) that were linked between ① and ⑦ to the macrocyclic lactam (Scheme 1). The lower right tripeptide part 1 (①–③) was prepared in five steps from tryptophan, while the upper left tetrapeptide 2 (④–⑦) required 13 steps from glutamic acid. Final oxidation of the δ-hydroxyleucine ⑤ resulted in the described ilamycins.
The synthesis of peptide fragment 1 was rather straightforward (Scheme 2). 2-(Trimethylsilyl)ethoxycarbonyl (Teoc)-protected tryptophan methylester 3 was subjected to a Pd-catalyzed N-tert-prenylation according to a protocol developed by Baran et al. [39]. Saponification of the ester moiety of 4 and peptide coupling with N-methylated Leu-OMe produced dipeptide 5, which was further elongated to tripeptide 1.
For the larger fragment 2, glutamic acid was converted into protected 8 (Scheme 3) according to a synthetic route developed during the synthesis of dysithiazolamide [40]. The glutamic acid was converted into the dimethyl ester and N-Boc protected before it was stereoselectively α-methylated at the sterically least-hindered ester moiety [41,42]. For the chemoselective reduction of the γ-ester 6, a second N-Boc-protecting group was introduced, and the sterically least-hindered ester functionality was reduced with DIBAL-H. Silyl protection of the primary alcohol and subsequent mono-Boc deprotection yielded 7. The methyl ester was saponified (to avoid α-methylation), and the Boc-amide was selectively N-methylated to 8 with NaH/MeI. The free carboxylic acid 8 was converted into the corresponding benzyl ester. TMSOTf/NEt3 was used for selective cleavage of the N-Boc-protecting group without affecting the OTBDPS group. The free amine could be coupled with Fmoc-protected alanine, and the C-terminal benzyl ester was cleaved by catalytic hydrogenation to provide the free acid 9.
Schöllkopf auxiliary 10 [43] was subjected to stereoselective crotylation to generate the C-terminal unsaturated amino acid of 2 (Scheme 3). Subsequent auxiliary cleavage provided N-Boc-protected amino acid 11, which was converted into the corresponding TMSE ester. Boc-deprotection and peptide coupling produced dipeptide 12. Subsequent Fmoc deprotection and coupling with 9 generated the linear tetrapeptide 2.
With the two major building blocks produced, ilamycin synthesis could proceed to the final step (Scheme 4). Mild saponification of the methylester 1 and coupling with Fmoc-deprotected 2 using (2-azabenzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyAOP) [44] yielded 13 without significant epimerization. Global deprotection with TBAF resulted in the linear heptapeptide, which was subjected to macrolactamization. While many peptide coupling reagents have been investigated, the best results were obtained using pentafluorophenyl diphenylphosphinate (FDPP) [45]. As a side product in addition to the expected cyclopeptide 14, the diphenylphosphinylated ester was formed, which could directly be converted into 14 by treatment with K2CO3 in methanol, providing an overall yield of 43% of the desired 14. Finally, only the primary OH-functionality needed to be oxidized. Depending on the oxidation protocol, both ilamycin E1 and F could be obtained. Ilamycin E1 was obtained as a single stereoisomer. Notably, ilamycin F is also available on a gram scale via fermentation, but the derivative E1, which is approximately 100-fold more potent, is not. Therefore, the authors developed a protocol to convert ilamycin F into intermediate 14 by reducing the mixed anhydride, permitting an interconversion of ilamycin F into ilamycin E1 [38].

4.2. Total Synthesis of Cyclomarins

The amino acids present in the cyclomarins are slightly more complex than in the ilamycins, and various synthetic approaches have been undertaken to produce these building blocks and partial structures of cyclomarin [46]. These are covered in a recent review [37], and therefore only the routes applicable to the synthesis of cyclomarins and derivatives will be discussed here.
The first synthesis of cyclomarin C was reported in 2004 by Yao and coworkers [47]. The unusual tert-prenylated β-hydroxy-tryptophan ① was obtained from indole derivative 15 (Scheme 5). This compound is available from indole via N-alkylation with ethyl-α-bromo-propionate, subsequent α-methylation of the ester, LAH-reduction, and acetylation [48]. Formylation and a subsequent Horner–Wadsworth–Emmons reaction yielded α,β-unsaturated ester 16, which could be subjected to a Sharpless aminohydroxylation [49]. Moderate yield and enantioselectivity of the desired β-hydroxytryptophan derivative 17 was obtained. Unfortunately, no comment was made concerning the regioselectivity of the reaction. Silylation of the β-hydroxy group and selective transesterification of the acetate gave rise to primary alcohol 18, which could be oxidized to the aldehyde and methenylated via Wittig reaction. Finally, the Cbz-protecting group from 19 was removed selectively without affecting the generated double bond. Furthermore, the free amine was Fmoc-protected after saponification of the ester. The use of the Fmoc- or Alloc-protecting group is essential for the synthesis of cyclomarins because other protecting groups, such as Boc, cannot be removed later on without side reactions, such as the elimination of the β-hydroxy functionality [50].
The synthesis of δ-hydroxyleucine building block ②, with the opposite configuration of the γ-methyl group than in amino acid ⑤ in the ilamycins, was obtained by classical asymmetric synthesis using chiral auxiliary chemistry (Scheme 6). According to Evans et al. [51], chiral oxazolidinone 21 was subjected as its titanium enolate in a Michael addition to tert-butyl acrylate to provide a good yield of 22 with high stereoselectivity. The imide was selectively reduced in the presence of the tert-butyl ester using LiBH4, and the resulting primary alcohol was O-benzoylated to 23. Acidic cleavage of the tert-butyl ester, activation of the carboxylic acid, and reapplication of the Evans auxiliary A provided oxazolidinone 24. Deprotonation of 24 and stereoselective azidation produced azide 25. Catalytic hydrogenation in the presence of Boc2O resulted in the formation of the N-Boc-protected amino derivative, which was saponified to the corresponding amino acid 26. The desired N-methyl group was introduced by conversion of 26 into the corresponding oxazolidinone 27, which was reduced using triethylsilane in presence of trifluoroacetic acid. Subsequent cleavage of the Boc-protecting group required its reintroduction to 28.
The unusual β-methoxyphenylalanine ④ was obtained from N-phthaloyl-protected phenylalanine 29, which was converted into the corresponding tert-butylamide 30 (Scheme 7). Oxygen functionality was introduced into the β-position by subjecting 30 to a Wohl–Ziegler bromination, providing a 1:1 diastereomeric mixture of the desired β-bromo derivative [52]. According to Easton et al., treatment of the diastereomeric mixture with AgNO3 in aqueous acetone produced the desired (2S,3R)-β-hydroxyphenylalanine enantio- and diastereoselectively [53]. The stereochemical outcome can be explained by a preferred conformation of the benzylic carbenium ion in the substitution step. The best selectivities were obtained with the tert-butylamide. Subsequent O-methylation provided the methoxy derivative 31, converted into the N-Boc-protected amino acid 32 under standard conditions.
Finally, the unsaturated amino acid ⑦ was obtained via an asymmetric chelate enolate Claisen rearrangement, developed by Kazmaier et al. (Scheme 8) [54,55]. Trifluoroacetyl (TFA)-protected glycine crotyl ester 33 was deprotonated and converted into a chelated aluminum ester enolate, which in the presence of quinidine underwent a [3,3]-sigmatropic rearrangement to unsaturated amino acid 34 with good yield and enantioselectivity. Epimerization of the α-stereogenic center was avoided by first converting 34 into the Boc-protected ester 35 and then, in a second step, into the corresponding phthaloyl-protected derivative 36. A direct epimerization-free conversion (34 to 36) was not possible. Ozonolysis of the double bond and subsequent Wittig reaction produced protected amino acid 37, finally converted into the Fmoc-protected acid 38.
After the desired building blocks were created, the synthesis of cyclomarin C and especially the best position for macrocyclization was investigated (Scheme 9) [47,56]. An attempt to align the synthesis to the biosynthetic pathway and to cyclize the linear heptapeptide precursor between the unusual tryptophan ① and the unsaturated amino acid ⑦ failed. Although obtaining the linear peptide in a [3+3+1] peptide fragment coupling strategy was straightforward, the final deprotection and ring closure yielded only trace amounts of the desired product. The same was true for attempts to cyclize the linear heptapeptide between the methoxyphenylalanine ④ and valine ⑤. The trial to cyclize between the sterically less demanding hydroxyleucine ② and alanine ③ failed early in the synthesis stage. All attempts to prolong the ①,② dipeptide at the N-terminus failed. Under the basic conditions for Fmoc-deprotection, spontaneous cyclization to the corresponding diketopiperazine occurred, comparable to the previously discussed biosynthetic side reaction, which resulted in the formation of the cyclomarazines. The ultimately successful route was the cyclization between the unsaturated amino acid ⑦ and the C-terminal N-methylleucine ⑥. The linear heptapeptide was obtained via a [4+3]-coupling strategy. An allyl ester was used as the C-terminal protecting group to avoid the basic reaction conditions required for the saponification of the C-terminal ester, which caused problems in previous cyclization attempts.
The desired tri- and tetrapeptide 39 and 40 were synthesized using classical peptide coupling reactions and a combination of Boc- and Fmoc-protecting groups (Scheme 10). Because of the acid lability of β-hydroxytryptophan, Fmoc had to be used after incorporating this building block into the growing peptide chain. The synthesis of the peptide fragments was straightforward. An adequate yield of the tripeptide 39 was obtained from N-Boc-valine 41 and N-methylleucine allyl ester 42. Boc-cleavage and coupling with methoxyphenylalanine 32 produced 39, which was also N-deprotected to tripeptide 44.
The synthesis of the tetrapeptide started with the coupling of protected δ-hydroxyleucine 28 with alanine allyl ester 45. After N-deprotection, the Fmoc-protected tryptophan 20 was coupled using Bop-Cl/DIPEA [57]. Careful removal of the Fmoc-protecting group from 47 and EDC/HOBT-coupling with the unsaturated building block 38 provided tetrapeptide 40. Finally, the C-terminal allyl ester was cleaved under mild Pd-catalyzed conditions, and the two peptide fragments were ready for the fragment coupling. An excellent yield of 48 was obtained using EDC/HOAt, which proved more suitable than HOBT. Subsequent deprotection of the C- and the N-terminus and removal of the OTBS-protecting group from the hydroxytryptophan provided the linear peptide precursor, which could be cyclized to 49 using PyBOP [58] under high dilution conditions and providing good yields. Finally, the benzoyl group had to be removed from the hydroxyleucine and cyclomarin C was purified via preparative HPLC.
The second synthesis of cyclomarin C and the first for cyclomarin A were reported in 2016 by Barbie and Kazmaier [59]. Both natural products differ only in the oxidation state of the prenylated β-hydroxytryptophan unit ①, which is epoxidized in cyclomarin A. Therefore, a synthetic protocol was developed which gave access to both tryptophan derivatives (Scheme 11). The synthesis started with a relatively new method for regioselective tert-prenylation of electron-demanding indoles [60]. Using indole ester 50, a palladium-catalyzed protocol delivered the required product 51 in almost quantitative yield. At 0 °C, no competitive n-prenylation was observed. In the next step, the activating ester functionality needed to be replaced by iodine. Saponification of the ester and heating the neat acid to 180 °C resulted in a clean decarboxylation to the N-prenylated indole, which could be iodinated in almost quantitative yield. Iodide 52 was used as a key building block for the synthesis of cyclomarin C, and after epoxidation, cyclomarin A. According to Yokohama et al. [61], 52 was subjected to a Sharpless dihydroxylation, which unfortunately demonstrated only moderate stereoselectivity. The best results were obtained with (DHQD)2Pyr as chiral ligand, but the ee did not exceed 80 % [62]. Subsequent tosylation of the primary OH-group and treatment with a base provided a good yield of the desired epoxide 53. The iodides 52 and 53 were next converted into organometallic reagents and reacted with a protected serinal. While the corresponding Grignard reagents provided only moderate yields and selectivities, zinc reagents were found to be superior. According to Knochel et al. [63,64], 52 was presumably converted into the indole–zinc–magnesium complex 54a, which was reacted with freshly prepared protected serinal to give the desired syn-configured 55a as a single diastereomer. In the case of the epoxyindole 53, a slightly different protocol was used. To avoid side reactions during the metalation step, 53 was lithiated at −78 °C with n-BuLi and transmetallated with ZnBr2 [63,64]. The zinc reagent 54b was directly reacted with the aldehyde to create 55b. According to NMR and HPLC, only two diastereomers (ratio 9:1) could be detected following the Sharpless dihydroxylation step. Obviously, the carbonyl addition also here was highly stereoselective. Next, the secondary OH-functionality was TBS-protected under the assumption that a primary OTBS-group could be removed selectively [65]. Notably, only a combination of TBSOTf and lutidine gave the desired product 56a in high yield, while all other methods failed and resulted in the decomposition of 55a. Interestingly, no complete conversion was obtained for 55b, but the silyl ether 56b was obtained as a single stereoisomer. Obviously, the undesirable diastereomer did not undergo silylation. Next, the primary silyl protecting group was removed using NH4F in MeOH [66]. The free alcohols 57 had to be oxidized to the desired carboxylic acids 59, which were found to be highly sensitive and not very stable. By far, the best results were obtained using a two-step protocol beginning with a Parikh–Doering oxidation [67]. The also very labile aldehydes were directly oxidized to the corresponding methyl esters 58 with N-iodosuccinimide in MeOH [68]. These are stable, can be stored under standard refrigeration, and should be saponified to the free acids 59 on demand.
A straightforward protocol was developed for the protected δ-hydroxyleucine ②, starting with the commercially available (S)-Roche ester, which was O-silylated to 60 (Scheme 12). Subsequent Dibal-H reduction provided the corresponding aldehyde, which was subjected to a Horner–Wadsworth–Emmons reaction using Schmidt’s phosphonoglycinate 61 [69]. The unsaturated amino acid 62 obtained was subjected to asymmetric hydrogenation [70] using (R)-MonoPhos as a chiral ligand [71,72]. Subsequent saponification of 63 and N-methylation yielded the desired building block 64.
The third unusual amino acid, β-methoxyphenylalanine ④, could be obtained similarly to the tryptophan building block ① (Scheme 13). Protected (R)-serine 65 was reduced to the corresponding aldehyde, which was subjected to a chelate-controlled aryl-metal addition. The addition of phenylmagnesium bromide provided an acceptable yield but only moderate diastereoselectivity (7:3). In contrast, in the presence of titanium salts, the desired coupling product 66 could be obtained as a single diastereomer in enantiomerically pure form. Further standard transformations yielded building block 32.
An alternative protocol, which also permitted the synthesis of substituted building blocks, was developed starting from commercially available chloramphenicol base 67 (Scheme 13) [73]. Thus, the amino diol was first converted stepwise into the protected derivative 68a. The nitro functionality could easily be reduced to the corresponding aniline derivative 68b, an ideal candidate for further structural variations via diazonium chemistry. Depending on the reaction conditions and additives used, several new derivatives 68c-e could be obtained, which could be oxidized to the corresponding amino acids 69a-d, while deamination of 68b provided the unsubstituted building block 32.
For the synthesis of the fourth, the unsaturated amino acid ⑦, also a chelate enolate Claisen rearrangement, was used starting with chiral ester 70 (Scheme 14) [74,75,76]. Rearrangement of the corresponding zinc enolate proceeded with complete chirality transfer and high stereoselectivity, and ester 71 was obtained after O-methylation. Ozonolysis provided the desired aldehyde, which was subjected to a Wittig reaction. However, only tiny amounts of the desired product could be obtained, even with a large excess of the Wittig reagents, which also caused the chiral aldehyde’s epimerization. Better results were obtained with a modified Julia–Kocienski reagent 72, normally used for (E)-selective olefination [77]. Under these conditions, the desired unsaturated building block 73 could be obtained almost epimerization-free. Saponification and change in the N-protecting group provided amino acid 74.
With all required building blocks synthesized, the linear synthesis of cyclomarins A and C started with protected N-methylleucine 75 (⑥) to cyclize the linear heptapeptide at the same position as achieved by Yao et al. (Scheme 15) [47,56]. The linear strategy was chosen to avoid epimerizations during fragment couplings, and three of the unusual building blocks were incorporated at the end of the synthesis, also allowing for modification of these building blocks and to obtain derivatives for structure-activity relationship (SAR) studies.
The hydrogenolysis of the Cbz-protecting group in dipeptide 76 was not a trivial task. The reaction required an H2 pressure of 20 bar to proceed, and two equivalents of HCl had to be added to avoid diketopiperazine formation. The hydrochloride salt was directly coupled with the activated amino acid 32 in the presence of excess base. The next steps were standard peptide couplings. BEP [78,79] was used to incorporate the sensitive tryptophan building blocks 59. The Alloc protecting group was removed, Pd-catalyzed, and the linear heptapeptide was cyclized using Yao’s protocol [47,56]. Finally, a two-step protocol was needed to remove the two OTBS protecting groups separately, providing good yields of cyclomarins A and C. Notably, cyclomarin D (desmethylcyclomarin C), missing only the N-methyl group of the δ-hydroxyleucin, was also obtained by this protocol [80].

5. Syntheses of Cyclomarin Derivatives

Given the outstanding biological properties of the cyclomarins, it is not surprising that multiple investigations have been undertaken to obtain modified cyclomarins for SAR studies.

5.1. Mutasyntheses of Cyclomarin Derivatives

In studies of cyclomarin biosynthesis, Moore et al. identified an N-prenyltransferase to prenylate tryptophan prior to loading the modified amino acid onto the NRPS [35]. A knockout mutant of Salinospora arenicola CNS-205 with a disrupted prenyltransferase gene failed to produce cyclomarins but did produce desprenylcyclomarin C, although at a 100-fold lower production rate. Obviously, tryptophan is not a good substrate for the cyclomarin NRPS, but other N-alkylated tryptophans are well accepted [34]. These can be obtained by simple alkylation of suitably protected tryptophan derivatives [81]. Feeding the bacteria with methylated and propargylated tryptophan resulted in the production of new cyclomarin derivatives CymM and CymP (Scheme 16).

5.2. Semisyntheses of Cyclomarin Derivatives

Researchers at Novartis observed that cyclomarin A might be a good candidate for drug development since it kills not only Mycobacterium tuberculosis (Mtb) but also the malaria parasite Plasmodium falciparum [82]. Thus, cyclomarin A is a rare example of a natural product with two distinct and specific modes of action. The researchers modified cyclomarin A, obtained by fermentation (Scheme 17) [83]. Ring-opening of the prenylepoxide with 1,3-propanediamine provided amine 83, which was linked to sepharose beads and processed by affinity chromatography to identify the target. Interestingly, 83 inhibits the growth of Mtb similarly to cyclomarin A [83,84]. Obviously, the epoxide of the N-prenyl side chain is not responsible for the biological activity, at least against Mtb. In contrast, replacing the terminal OH-group of the δ-hydroxyleucine ② by an N-methylanilin (84) caused a significant drop (>200 fold) in activity [83].
Notably, the amine 77, which was very active against Mtb, demonstrated little activity against Plasmodium falciparum. Therefore, the Novartis researchers also synthesized acetylenic amine 85 for target fishing [82]. This compound was almost as active as cyclomarin A in biochemical assays toward the biological target PfAp3Aase. As an inactive control, a “minimized” cyclomarin 86 with a missing tryptophan side chain was used. This compound was obtained by retro aldol reaction.

5.3. Total Synthesis of Cyclomarin Derivatives

Retro aldol reaction of the β-hydroxytryptophan seems to be a serious stability issue, also during synthesis. This building block undergoes the discussed side reaction proceeding under slightly basic conditions. Under acidic conditions, water is rapidly eliminated, resulting in the formation of the α,β-unsaturated dehydrotryptophan derivative. To avoid these problems, Kazmaier et al. synthesized a series of cyclomarin derivatives containing non-hydroxylated tryptophans (desoxycyclomarins), e.g., the building blocks found in ilamycins/rufomycin [85,86]. N-Isopropyltryptophan was obtained via Negishi coupling of 3-iodo-N-isopropylindole with protected zincated iodoalanine [86]. Other derivatives can be obtained by an improved protocol for tryptophan alkylations [81]. Several modifications have also been made on the β-methoxyphenylalanine unit ④ [73]. Other derivatives were synthesized utilizing further modifications on building blocks ② and ⑦ (Figure 4).

6. Biological Activities and Mode of Action

6.1. Biological Activities of Ilamycins/Rufomycins

Both the ilamycins [14,15] and rufomycins [16,17] were isolated independently from Streptomycetes in 1962 as new antibiotics, active against acid-fast bacteria, especially Mycobacteria. Ilamycin A was reported to inhibit Mycobacterium 607 at 0.5 μg/mL, while ilamycin B was less active (3 μg/mL). The rufomycins were reported to be highly active against Mycobacterium smegmatis (RufA: 0.2 μg/mL, RufB: 0.5 μg/mL) and Mycobacterium tuberculosis (RufA: 0.1–0.4 μg/mL, RufB: 1–5 μg/mL), also strains resistant to other antibiotics such as streptomycin (SM), neomycin (NM), kanamycin (KM), and isonicotinic acid hydrazide (INHA. The compounds are almost inactive against other Gram-positive and Gram-negative bacteria, fungi, and yeasts. In addition, no significant toxicity was observed on four-week-old mice by intraperitoneal injection (Ruf A, LD0 200 mg/kg and LD100 360 mg/kg) [16].
Ma and Ju et al. recently isolated 12 new ilamycin analogs (IlaG-R) from a 200 L scale culture of mutant Streptomyces atratus ZH16 ΔilaR. The analogs demonstrated a slightly different oxidation pattern compared to the previously isolated ilamycins [27,28]. Most derivatives showed the same antibacterial activity as the other ilamycins and rufomycins with MIC’s in the range of 1−2 μM against Mycobacterium tuberculosis, while the most active examples thus far have been ilamycin E and J (Figure 5), both more active than rifampicin used as a positive control.
Based on the bioassay data, some structure-activity relationships became evident. Cyclized compounds such as IlaE and IlaJ demonstrated greater activity than open-chain leucine derivatives such as IlaB, IlaD, or IlaF (Figure 1). Oxidation of the prenyl side chain did not affect activity. The nitro group on the tyrosine seems to play an important role [27,28].
In 2020, Pauli et al. isolated eight new rufomycins (rufNBZ1-NBZ8) together with five already known derivatives from the Streptomyces atratus strain MJM3502 [29]. Analogous to the ilamycins, the most active derivatives contain a cyclic oxidized leucine such as RufNBZ8 or the previously isolated Ruf I (Figure 6) with an MIC (M. tuber. HR37v) similar to rifampicin (0.03 μM). Ruf I maintained activity against monoresistant, MDR, and XDR strains, indicating that the Rufs most likely have a different molecular target than current drugs used in TB therapy. Additionally, Ruf I retained its activity against strains from the five global M. tuberculosis clades representative of clinical TB disease worldwide [87]. Especially interesting is its activity against M. abscessus, one of the more difficult-to-treat mycobacteria [88].
Detailed studies indicated that the ilamycins/rufomycins inhibit ClpC1, an enzyme currently not targeted for TB treatment. ClpC1 is the ATP-dependent homolog of the ClpC class of chaperone proteins present in M. tuberculosis [89] and is highly conserved among mycobacteria. Unlike in many other bacteria, ClpC proteins are essential for the viability of mycobacteria, especially M. tuberculosis. In this species, the strictly regulated ClpC1 associates with the proteolytic domains, ClpP1 and ClpP2, and together they are responsible for waste protein degradation within the cell [90]. Without functional ClpC1, cellular protein degradation is reduced or stopped completely. Ruf I significantly decreases the proteolytic capabilities of the ClpC1/P1/P2 complex while having no significant effect on the ATPase activity of ClpC1 [87]. In this respect, it differs from ecumicin (Ecu), another anti-tubercular cyclic peptide, which inhibits ClpC1 but stimulates ATPase activity. Details of the binding topology and chemical mode of (inter)action of these cyclopeptides were reported by Cho et al. [91]. The X-ray structure of a complex of the N-terminal helical domain (NTD) of ClpC1 and Ruf I reveals distinct differences from the corresponding ClpC1-NTD-cyclomarin A structure. Surprisingly, the complex structure shows that the epoxide moiety of Ruf I is opened and covalently bound to ClpC1-NTD via the sulfur atom of a methionine in the binding pocket [92,93].
Although the anti-tubercular activity is the most prominent effect of ilamycins/rufomycins, certain derivatives show some anti-cancer activities, while others do not. IlaC (Ruf I) was found to be preferentially cytotoxic towards triple-negative breast cancer (TNBC) cell lines, the most aggressive subtype of breast cancer with poor prognoses. IlaC can induce Bax/Bcl-2-related caspase-dependent apoptosis and inhibit migration and invasion in TNBC by suppressing IL-6-induced STAT3 phosphorylation [94]. IlaE, but not IlaF, decreases cell viability, inhibits G1/S cell cycle progression, and promotes apoptosis in the TNBC cell lines HCC1937 (IC50 14.2 μM) and MDA-MB-468 (IC50 24.5 μM). It promotes apoptosis via activation of endoplasmic reticulum (ER) stress, increasing CHOP expression and down-regulating the expression of anti-apoptotic protein Bcl-2 [94].

6.2. Biological Activities of Cyclomarins

Fenical and Clardy et al., who isolated the cyclomarins A−C in 1999, reported that the major metabolite cyclomarin A (CymA) showed anti-inflammatory activity in vivo and in vitro [30]. Lateron, Pittayakhajonwut et al. reported that CymC shows anti-malarial activity against multidrug-resistant Plasmodium falciparum strains (IC50 0.25 μM) as well as anti-TB activity (MIC: 0.1 μM) [95]. No significant activity was observed against cancer cells or Candida albicans (IC50 > 50 μM). Schmitt et al. at Novartis investigated the mode of action in detail [83]. CymA was found to bind specifically and with a high affinity to ClpC1 and did not interfere with ATP binding by the two ATPase domains of ClpC1. The antimycobacterial activity of cyclomarin derivatives correlates well with binding to ClpC1. For example, amino alcohol 83 (Scheme 17) demonstrated high affinity (MIC: 0.1 μM), while no binding was observed for the inactive amine 84. The hydroxy functionality on leucine ② is clearly important for binding, but not the epoxide.
The exact binding of CymA toward the NTD of ClpC1 was determined by high-resolution co-crystal structure analysis [84]. The overall sequence identity of ClpC1 from various Mycobacterium species is close to 95%, but the NTD of mycobacterial ClpC1 is 100% conserved. This phenomenon explains why all tested mycobacteria were found to be sensitive to CymA. Based on the structure of the complex, several mutations were engineered into ClpC1, which showed reduced CymA binding in vitro. The ClpC1 mutants were overexpressed in mycobacteria and two showed resistance to CymA, providing clear evidence that ClpC1 is the target of CymA.
Using NMR and small-angle X-ray scattering, Schanda and Fraga et al. demonstrated that arginine-phosphate binding to the ClpC1 NTD induces millisecond dynamics [96]. Cyclomarin binding to this domain specifically blocks these dynamics. Based on these results, a proposed mechanism of action involves the cyclomarin-induced restriction of ClpC1 dynamics, which modulates the chaperone enzymatic activity leading eventually to cell death [96]. Very recently, Mogk et al. showed that CymA activates an ATP-driven bacterial AAA+ protease (e.g., ClpP) and that cell death is induced by uncontrolled proteolytic activity of these enzymes [97].
However, anti-TB activity is not the only interesting feature of the cyclomarins. Schmitt et al. showed that CymA is a potent growth inhibitor of Plasmodium falciparum, and its molecular target, diadenosine triphosphate hydrolase (PfAp3Aase), was identified by chemical proteomics [82]. CymA is a specific inhibitor of the plasmodial enzyme (IC50: 0.004 μM) but not of the closest human homolog hFHIT (IC50 > 10 μM). Co-crystallization experiments demonstrated a unique inhibitor binding mode. One molecule of CymA binds a dimeric PfAp3Aase and prevents the formation of the enzyme-substrate complex. These results validate PfAp3Aase as a new drug target for the treatment of malaria. Thus, CymA is a rare example of a natural product with two distinct and specific modes of action.
Unfortunately, CymA as a natural product lacks satisfactory pharmacokinetic properties, making it challenging for optimization into an (orally) bioavailable drug. Therefore, Kazmaier et al. tried to simplify the complex structure of the cyclomarins without losing significant biological activity. Because the β-hydroxytryptophan unit ① is the most critical building block, they removed the hydroxy functionality completely, and the desoxycyclomarins obtained were further modified on the prenyl side chain of ①, the hydroxylated leucine ②, the β-methoxyphenylalanine ④ and the unsaturated amino acid ⑦ [37,73,85,86]. Selected biological data are summarized in Table 1.
Certain modifications at R1 were well-tolerated (series 87). Reduction to an isopropyl group (87c) provides an especially promising simplification retaining antimycobacterial activity. In general, manipulations at this position do not result in dramatic effects on potency measured against Mtb and Pfalcp. Interestingly, the methyl group in 87d is an appropriate balance between reducing synthetic complexity and loss of activity.
Results obtained for the modifications at R2 were consistent with the data obtained by X-ray structure analysis [82]. In the case of Pfalcp, where this residue is completely buried between the target and the ligand scaffold, large changes are not accepted. However, it is important that removing the terminal methyl group in the cis position of the γ,δ-unsaturated side chain led to an equivalent or even slightly improved activity. Further simplifications, however, are not advisable, as they lead to dramatic activity losses, which are seen in the comparison of 87a and 88a. In contrast, the anti-TB activity was not influenced.
Removal of the methyl group at R3 led to a decrease in potency against both pathogens (89). This result was indeed expected for the Mtb target ClpC1-NTD [96]. This group interacts well with the target, which is also closely packed with the indole motif of the tryptophan core. However, it is not yet clear why deletion of this methyl residue impairs activity towards Pfalcp.
Modifications of R4 on β-methoxyphenylalanine ④ were also well tolerated (90). The amino- and azido-derivatives 90a and 90b were equipotent to cyclomarin C, and the nitro compound 90c was even twice as active. Only in the case of bromo derivative 90d was a significant drop in activity observed.

7. Conclusions

The ilamycins/rufomycins and the cyclomarins are highly interesting marine cycloheptapeptides characterized by their incorporation of unusual amino acids. The natural products are produced by Streptomyces sp. and show potent activity against a range of mycobacteria, including multidrug-resistant strains of Mycobacterium tuberculosis. No significant activity has been observed towards other Gram-positive and Gram-negative bacteria or fungi.
The cyclomarins are also very potent inhibitors of Plasmodium falciparum, the organism that causes malaria. Biosynthetically, the cyclopeptides are obtained via a heptamodular NRPS that directly incorporates some of the nonproteinogenic amino acids, while oxidations at certain positions allow the compounds to proceed to protein-bound biosynthetic intermediates. Cyclized ilamycins/rufomycins are obtained by oxidative post-NRPS cyclization of leucine ⑦, the last introduced amino acid in the biosynthesis. A wide range of derivatives can be obtained by fermentation, while bioengineering also allows the mutasynthesis of derivatives, especially cyclomarins. Other derivatives are accessible by semisynthesis or total syntheses, reported for both natural product classes. Some of these derivatives were used to identify the biological targets of these peptides. The anti-TB activity results from the binding of the peptides to the N-terminal domain (NTD) of the protease ClpC1, causing cell death by the uncontrolled proteolytic activity of associated enzymes.
Diadenosine triphosphate hydrolase (PfAp3Aase) was found to be the active target of the cyclomarins in Plasmodia, and this enzyme might be a good candidate for the treatment of malaria. SAR studies of natural and synthetic derivatives on the ilamycins/rufomycins and cyclomarins indicate which parts of the molecules can be simplified/modified without losing activity towards either target.

Author Contributions

U.K. and L.J., writing review and editing. All authors have read and agreed to the published version of the manuscript.


This research was funded by Saarland University and received no external funding.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.


  1. Carroll, A.R.; Copp, B.R.; Davis, R.A.; Keyzers, R.A.; Prinsep, M.R. Marine natural products. Nat. Prod. Rep. 2020, 37, 175–223. [Google Scholar] [CrossRef]
  2. Carroll, A.R.; Copp, B.R.; Davis, R.A.; Keyzers, R.A.; Prinsep, M.R. Marine natural products. Nat. Prod. Rep. 2021, 38, 362–413. [Google Scholar] [CrossRef] [PubMed]
  3. Barreca, M.; Spane, V.; Montalbano, A.; Cueto, M.; Marrero, A.R.D.; Deniz, I.; Erdogan, A.; Bilela, L.L.; Moulin, C.; Taffin-de-Givenchy, E.; et al. Marine Anticancer Agents: An Overview with a Particular Focus on Their Chemical Classes. Mar. Drugs 2020, 18, 619. [Google Scholar] [CrossRef] [PubMed]
  4. McCauley, E.P.; Pina, I.C.; Thompson, A.D.; Bashir, K.; Weinberg, M.; Kurz, S.L.; Crews, P. Highlights of marine natural products having parallel scaffolds found from marine-derived bacteria, sponges, and tunicates. J. Antibiot. 2020, 73, 504–525. [Google Scholar] [CrossRef] [PubMed]
  5. Qamar, H.; Hussain, K.; Soni, A.; Khan, A.; Hussain, T.; Chenais, B. Cyanobacteria as natural therapeutics and pharmaceutical potential: Role in antitumor activity and as nanovectors. Molecules 2021, 26, 247. [Google Scholar] [CrossRef] [PubMed]
  6. Njoroge, M.; Njuguna, N.M.; Mutai, P.; Ongarora, D.S.B.; Smith, P.W.; Chibale, K. Recent approaches to chemical discovery and development against malaria and the neglected tropical diseases human african trypanosomiasis and schistosomiasis. Chem. Rev. 2014, 114, 11138–11163. [Google Scholar] [CrossRef] [PubMed]
  7. WHO. Available online: (accessed on 30 July 2021).
  8. De Opitz, C.L.M.; Sass, P. Tackling antimicrobial resistance by exploring new mechanisms of antibiotic action. Future Microbiol. 2020, 15, 703–708. [Google Scholar] [CrossRef] [PubMed]
  9. Dooley, K.E.; Park, J.G.; Swindells, S.; Allen, R.; Haas, D.W.; Cramer, Y.; Aweeka, F.; Wiggins, I.; Gupta, A.; Lizak, P.; et al. Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS clinical trials group study A5267. J. Acq. Imm. Def. 2012, 59, 455–462. [Google Scholar] [CrossRef] [PubMed][Green Version]
  10. Zumla, A.; Nahid, P.; Cole, S.T. Advances in the development of new tuberculosis drugs and treatment regimens. Nat. Rev. Drug Discov. 2013, 12, 388–404. [Google Scholar] [CrossRef]
  11. Igarashi, M.; Ishizaki, Y.; Takahashi, Y. New antituberculous drugs derived from natural products: Current perspectives and issues in antituberculous drug development. J. Antibiot. 2018, 71, 15–25. [Google Scholar] [CrossRef]
  12. Lee, H.; Suh, J.W. Anti-tuberculosis lead molecules from natural products targeting Mycobacterium tuberculosis ClpC1. J. Ind. Microbiol. Biotechnol. 2016, 43, 205–212. [Google Scholar] [CrossRef]
  13. Newman, D.J.; Cragg, G.M. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J. Nat. Prod. 2012, 75, 311–335. [Google Scholar] [CrossRef] [PubMed][Green Version]
  14. Nakayama, Y.; Takita, T.; Ozawa, H.; Umezawa, H.; Tahara, K. Studies on ilamycin. J. Antibiot. 1962, 15, 49–50. [Google Scholar]
  15. Takita, T.; Ohi, K.; Maeda, K.; Okami, Y.; Umezawa, H. New antibiotics, ilamycins. J. Antibiot. 1962, 15, 46–48. [Google Scholar]
  16. Higashidani, E.; Ueyanagi, J.; Shibata, M.; Nakazawa, K.; Miyake, A.; Iwasaki, H.; Yamamoto, H. Studies on Streptomycetes. 2. Rufomycin A and A, new antituberculous antibiotics. Agric. Biol. Chem. 1962, 26, 234–237. [Google Scholar]
  17. Shibata, M.; Yamamoto, H.; Higashidani, E.; Nakazawa, K. Studies on Streptomycetes. 1. Streptromyces atratus nov. sp. producing new antituberculous antibiotics rufomycin A and B. Agric. Biol. Chem. 1962, 26, 228–233. [Google Scholar]
  18. Cary, L.W.; Takita, T.; Ohnishi, M. Study of secondary structure of ilamycin-B1 by 300 MHz proton magnetic resonance. FEBS Lett. 1971, 17, 145–148. [Google Scholar] [CrossRef][Green Version]
  19. Iitaka, Y.; Nakamura, H.; Takada, K.; Takita, T. X-RAY study of ilamycin B1, a cyclic heptapeptide antibiotic. Acta Cryst. B 1974, 30, 2817–2825. [Google Scholar] [CrossRef]
  20. Iwasaki, H.; Witkop, B. New methods for nonenzymatic peptide cleavage. Electrolytic differential + solvolytic cleavage of antibiotic cyclopeptide rufymacin. J. Am. Chem. Soc. 1964, 86, 4698–4708. [Google Scholar] [CrossRef]
  21. Takita, T. Amino acid sequence of ilamycin and ilamycin B. J. Antibiot. 1963, 16, 211–212. [Google Scholar]
  22. Takita, T.; Maeda, K.; Naganawa, H.; Umezawa, H. Structures of ilamycin and ilamycin B2. J. Antibiot. 1964, 17, 129–131. [Google Scholar]
  23. Takita, T.; Naganawa, H.; Maeda, K.; Umezawa, H. The structural diffference among ilamycin, ilamycin C1 and ilamycin C2. J. Antibiot. 1965, 18, 135–136. [Google Scholar]
  24. Fujino, M.; Kamiya, T.; Miyake, A.; Iwasaki, H.; Ueyanagi, J. Tryptophan moiety of rufomycin homologs. Chem. Pharm. Bull. 1964, 12, 390–1392. [Google Scholar] [CrossRef] [PubMed][Green Version]
  25. Takita, T.; Naganawa, H.; Maeda, K.; Umezawa, H. Further studies on tryptophan parts of ilamycins. J. Antibiot. 1964, 17, 264–265. [Google Scholar]
  26. Takita, T.; Naganawa, H. L-2-Amino-4-hexenoic acid in ilamycins. J. Antibiot. 1963, 16, 246. [Google Scholar]
  27. Ma, J.Y.; Huang, H.B.; Xie, Y.C.; Liu, Z.Y.; Zhao, J.; Zhang, C.Y.; Jia, Y.X.; Zhang, Y.; Zhang, H.; Zhang, T.Y.; et al. Biosynthesis of ilamycins featuring unusual building blocks and engineered production of enhanced anti-tuberculosis agents. Nat. Commun. 2017, 8, 391. [Google Scholar] [CrossRef][Green Version]
  28. Sun, C.L.; Liu, Z.Y.; Zhu, X.C.; Fan, Z.Y.; Huang, X.M.; Wu, Q.L.; Zheng, X.H.; Qin, X.J.; Zhang, T.Y.; Zhang, H.; et al. Antitubercular ilamycins from marine-derived Streptomyces atratus SCSIO ZH16 Δ ilaR. J. Nat. Prod. 2020, 83, 1646–1657. [Google Scholar] [CrossRef]
  29. Zhou, B.; Shetye, G.; Yu, Y.; Santarsiero, B.D.; Klein, L.L.; Abad-Zapatero, C.; Wolf, N.M.; Cheng, J.; Jin, Y.; Lee, H.; et al. Antimycobacterial rufomycin analogues from Streptomyces atratus strain MJM3502. J. Nat. Prod. 2020, 83, 657–667. [Google Scholar] [CrossRef][Green Version]
  30. Renner, M.K.; Shen, Y.C.; Cheng, X.C.; Jensen, P.R.; Frankmoelle, W.; Kauffman, C.A.; Fenical, W.; Lobkovsky, E.; Clardy, J. Cyclomarins A-C, new antiinflammatory cyclic peptides produced by a marine bacterium (Streptomyces sp.). J. Am. Chem. Soc. 1999, 121, 11273–11276. [Google Scholar] [CrossRef]
  31. Kumamoto, T.; Koshino, H.; Watanabe, D.; Matsumoto, Y.; Aoyama, K.; Harada, K.; Ishikawa, T.; Mikami, Y. M10709, a new peptide antibiotic from clinically isolated Streptomyces sp. Heterocycles 2010, 80, 281–288. [Google Scholar]
  32. Li, L.; MacIntyre, L.W.; Ali, T.; Russo, R.; Koirala, B.; Hernandez, Y.; Brady, S.F. Biosynthetic interrogation of soil metagenomes reveals metamarin, an uncommon cyclomarin congener with activity against Mycobacterium tuberculosis. J. Nat. Prod. 2021, 84, 1056–1066. [Google Scholar] [CrossRef]
  33. Tomita, H.; Katsuyama, Y.; Minami, H.; Ohnishi, Y. Identification and characterization of a bacterial cytochrome P450 monooxygenase catalyzing the 3-nitration of tyrosine in rufomycin biosynthesis. J. Biol. Chem. 2017, 292, 15859–15869. [Google Scholar] [CrossRef] [PubMed][Green Version]
  34. Schultz, A.W.; Lewis, C.A.; Luzung, M.R.; Baran, P.S.; Moore, B.S. Functional characterization of the cyclomarin/cyclomarazine prenyltransferase CymD directs the biosynthesis of unnatural cyclic peptides. J. Nat. Prod. 2010, 73, 373–377. [Google Scholar] [CrossRef] [PubMed][Green Version]
  35. Schultz, A.W.; Oh, D.C.; Carney, J.R.; Williamson, R.T.; Udwary, D.W.; Jensen, P.R.; Gould, S.J.; Fenical, W.; Moore, B.S. Biosynthesis and structures of cyclomarins and cyclomarazines, prenylated cyclic peptides of marine actinobacterial origin. J. Am. Chem. Soc. 2008, 130, 4507–4516. [Google Scholar] [CrossRef] [PubMed]
  36. He, J.Q.; Wei, X.; Yang, Z.J.; Li, Y.; Ju, J.H.; Ma, J.Y. Characterization of regulatory and transporter genes in the biosynthesis of anti-tuberculosis ilamycins and production in a heterologous host. Mar. Drugs 2020, 18, 216. [Google Scholar] [CrossRef][Green Version]
  37. Kiefer, A.; Kazmaier, U. Syntheses of cyclomarins—Interesting marine natural products with distinct mode of action towards malaria and tuberculosis. Synthesis 2019, 51, 107–121. [Google Scholar] [CrossRef][Green Version]
  38. Cheng, Y.Y.; Tang, S.B.; Guo, Y.; Ye, T. Total synthesis of anti-tuberculosis natural products ilamycins E-1 and F. Org. Lett. 2018, 20, 6166–6169. [Google Scholar] [CrossRef]
  39. Luzung, M.R.; Lewis, C.A.; Baran, P.S. Direct, chemoselective N-tert-prenylation of indoles by C-H functionalization. Angew. Chem. Int. Ed. 2009, 48, 7025–7029. [Google Scholar] [CrossRef][Green Version]
  40. Arda, A.; Soengas, R.G.; Nieto, M.I.; Jimenez, C.; Rodriguez, J. Total synthesis of (-)-dysithiazolamide. Org. Lett. 2008, 10, 2175–2178. [Google Scholar] [CrossRef]
  41. Hanessian, S.; Margarita, R. 1,3-asymmetric induction in dianionic allylation reactions of amino acid derivatives-synthesis of functionally useful enantiopure glutamates, pipecolates and pyroglutamates. Tetrahedron Lett. 1998, 39, 5887–5890. [Google Scholar] [CrossRef]
  42. Padron, J.M.; Kokotos, G.; Martin, T.; Markidis, T.; Gibbons, W.A.; Martin, V.S. Enantiospecific synthesis of alpha-amino acid semialdehydes: A key step for the synthesis of unnatural unsaturated and saturated alpha-amino acids. Tetrahedron Asymmetry 1998, 9, 3381–3394. [Google Scholar] [CrossRef]
  43. Schöllkopf, U.; Groth, U.; Deng, C. Asymmetric synthesis via heterocyclic intermediates. 6. Enantioselective synthesis of (R)-amino acids using valine as a chiral agent. Angew. Chem. Int. Ed. Engl. 1981, 20, 798–799. [Google Scholar] [CrossRef]
  44. Albericio, F.; Cases, M.; Alsina, J.; Triolo, S.A.; Carpino, L.A.; Kates, S.A. On the use of PyAOP, a phosphonium salt derived from HOAt, in solid-phase peptide synthesis. Tetrahedron Lett. 1997, 38, 4853–4856. [Google Scholar] [CrossRef]
  45. Chen, S.Q.; Xu, J.C. Pentafluorophenyl diphenylphosphinate—A new efficient coupling reagent in peptide chemistry. Tetrahedron Lett. 1991, 32, 6711–6714. [Google Scholar] [CrossRef]
  46. Sathish, K.; Reddy, G.P.K.; Mainkar, P.S.; Chandrasekhar, S. Synthesis of the ‘southern’ tripeptide of Cyclomarins A and C having novel anti-tuberculocidal mode of action. Tetrahedron Asymmetry 2011, 22, 1568–1573. [Google Scholar] [CrossRef]
  47. Wen, S.J.; Yao, Z.J. Total synthesis of cyclomarin C. Org. Lett. 2004, 6, 2721–2724. [Google Scholar] [CrossRef]
  48. Wen, S.J.; Zhang, H.W.; Yao, Z.J. Synthesis of a fully protected (2S,3R)-N-(1′,1′-dimethyl-2′-propenyl)-3-hydroxytryptophan from tryptophan. Tetrahedron Lett. 2002, 43, 5291–5294. [Google Scholar] [CrossRef]
  49. Tao, B.; Schlingloff, G.; Sharpless, K.B. Reversal of regioselection in the asymmetric aminohydroxylation of cinnamates. Tetrahedron Lett. 1998, 39, 2507–2510. [Google Scholar] [CrossRef]
  50. Barbie, P.; Kazmaier, U. Synthesis of fully protected, reverse N-prenylated (2S,3R)-3-hydroxytryptophan, a unique building block of the cyclomarins. Org. Biomol. Chem. 2015, 13, 9267–9275. [Google Scholar] [CrossRef] [PubMed][Green Version]
  51. Evans, D.A.; Ripin, D.H.B.; Halstead, D.P.; Campos, K.R. Synthesis and absolute stereochemical assignment of (+)-miyakolide. J. Am. Chem. Soc. 1999, 121, 6816–6826. [Google Scholar] [CrossRef]
  52. Easton, C.J.; Hutton, C.A.; Roselt, P.D.; Tiekink, E.R.T. Synthesis and molecular structure of stable derivatives of (E)-dehydrophenylalanine and (Z)-dehydrophenylalanine. Aust. J. Chem. 1991, 44, 687–694. [Google Scholar] [CrossRef]
  53. Easton, C.J.; Hutton, C.A.; Roselt, P.D.; Tiekink, E.R.T. Stereocontrolled synthesis of β-hydroxyphenylalanine and β-hydroxytyrosine derivatives. Tetrahedron 1994, 50, 7327–7340. [Google Scholar] [CrossRef]
  54. Kazmaier, U.; Krebs, A. Synthesis of chiral γ,δ-unsaturated amino acids by asymmetric ester enolate Claisen rearrangement. Angew. Chem. Int. Ed. Engl. 1995, 34, 2012–2014. [Google Scholar] [CrossRef]
  55. Kazmaier, U.; Mues, H.; Krebs, A. Asymmetric chelated Claisen rearrangements in the presence of chiral ligands—Scope and limitations. Chem. Eur. J. 2002, 8, 1850–1855. [Google Scholar] [CrossRef]
  56. Wen, S.J.; Hu, T.S.; Yao, Z.J. Macrocyclization studies and total synthesis of cyclomarin C, an anti-inflammatory marine cyclopeptide. Tetrahedron 2005, 61, 4931–4938. [Google Scholar] [CrossRef]
  57. Cabre, J.; Palomo, A.L. New experimental strategies in amide synthesis using N,N-Bis-2-oxo-3-oxazolidinyl phosphordiamidic chloride. Synthesis 1984, 413–417. [Google Scholar] [CrossRef]
  58. Coste, J.; Lenguyen, D.; Castro, B. PYBOP—A new peptide coupling reagent devoid of toxic byproducts. Tetrahedron Lett. 1990, 31, 205–208. [Google Scholar] [CrossRef]
  59. Barbie, P.; Kazmaier, U. Total Synthesis of Cyclomarin A, a Marine Cycloheptapeptide with Anti-Tuberculosis and Anti-Malaria Activity. Org. Lett. 2016, 18, 204–207. [Google Scholar] [CrossRef] [PubMed]
  60. Johnson, K.F.; Van Zeeland, R.; Stanley, L.M. Palladium-catalyzed synthesis of N-tert-prenylindoles. Org. Lett. 2013, 15, 2798–2801. [Google Scholar] [CrossRef][Green Version]
  61. Sugiyama, H.; Shioiri, T.; Yokokawa, F. Syntheses of four unusual amino acids, constituents of cyclomarin A. Tetrahedron Lett. 2002, 43, 3489–3492. [Google Scholar] [CrossRef]
  62. Della Sala, G.; Izzo, I.; Spinella, A. A Pd-mediated approach to the synthesis of an unusual β-hydroxytryptophan amino acid constituent of cyclomarin A. Synlett 2006, 1319–1322. [Google Scholar]
  63. Metzger, A.; Bernhardt, S.; Manolikakes, G.; Knochel, P. MgCl2-accelerated addition of functionalized organozinc reagents to aldehydes, ketones, and carbon dioxide. Angew. Chem. Int. Ed. 2010, 49, 4665–4668. [Google Scholar] [CrossRef] [PubMed]
  64. Piller, F.M.; Metzger, A.; Schade, M.A.; Haag, B.A.; Gavryushin, A.; Knochel, P. Preparation of polyfunctional arylmagnesium, arylzinc, and benzylic zinc reagents by using magnesium in the presence of LiCl. Chem. Eur. J. 2009, 15, 7192–7202. [Google Scholar] [CrossRef]
  65. Corey, E.J.; Venkateswarlu, A. Protection oh hydroxyl groups as tert-Butyldimethylsilyl derivatives. J. Am. Chem. Soc. 1972, 94, 6190–6191. [Google Scholar] [CrossRef]
  66. Futagawa, S.; Inui, T.; Shiba, T. Nuclear magnetic-resonance study of stereoisomeric 2-oxazolidone and 2-phenyl-2-oxazoline derivatives of α-amino-β-hydroxy acids. Bull. Chem. Soc. Jpn. 1973, 46, 3308–3310. [Google Scholar] [CrossRef][Green Version]
  67. Parikh, J.R.; Doering, W.V.E. Sulfur trioxide in oxidation of alcohols by dimethyl sulfoxide. J. Am. Chem. Soc. 1967, 89, 5505–5507. [Google Scholar] [CrossRef]
  68. McDonald, C.; Holcomb, H.; Kennedy, K.; Kirkpatrick, E.; Leathers, T.; Vanemon, P. N-iodosuccinimide-mediated conversion of aldehydes to methyl esters. J. Org. Chem. 1989, 54, 1213–1215. [Google Scholar] [CrossRef]
  69. Schmidt, U.; Griesser, H.; Leitenberger, V.; Lieberknecht, A.; Mangold, R.; Meyer, R.; Riedl, B. Amino-acids and peptides. 81. Diastereoselective formation of (Z)-didehydroamino acid-esters. Synthesis 1992, 487–490. [Google Scholar] [CrossRef]
  70. Schmidt, U.; Lieberknecht, A.; Kazmaier, U.; Griesser, H.; Jung, G.; Metzger, J. Amino-acids and peptides. 75. Synthesis of dihydroxyamino and trihydroxyamino acids—Construction of lipophilic tripalmitoyldihydroxy-α-amino acids. Synthesis 1991, 49–55. [Google Scholar] [CrossRef]
  71. Panella, L.; Aleixandre, A.M.; Kruidhof, G.J.; Robertus, J.; Feringa, B.L.; de Vries, J.G.; Minnaard, A.J. Enantioselective Rh-catalyzed hydrogenation of N-formyl dehydroamino esters with monodentate phosphoramidite ligands. J. Org. Chem. 2006, 71, 2026–2036. [Google Scholar] [CrossRef][Green Version]
  72. Van den Berg, M.; Minnaard, A.J.; Schudde, E.P.; van Esch, J.; de Vries, A.H.M.; de Vries, J.G.; Feringa, B.L. Highly enantioselective rhodium-catalyzed hydrogenation with monodentate ligands. J. Am. Chem. Soc. 2000, 122, 11539–11540. [Google Scholar] [CrossRef][Green Version]
  73. Kiefer, A.; Kazmaier, U. Synthesis of modified β-methoxyphenylalanines via diazonium chemistry and their incorporation in desoxycyclomarin analogues. Org. Biomol. Chem. 2019, 17, 88–102. [Google Scholar] [CrossRef] [PubMed]
  74. Kazmaier, U.; Schneider, C. Stereoselective synthesis of unsaturated polyhydroxylated amino acids via ester enolate Claisen rearrangement. Synlett 1996, 10, 975–977. [Google Scholar] [CrossRef]
  75. Kazmaier, U.; Schneider, C. Application of the asymmetric chelate enolate Claisen rearrangement to the synthesis of unsaturated polyhydroxylated amino acids. Synthesis 1998, 1321–1326. [Google Scholar] [CrossRef]
  76. Kazmaier, U.; Schneider, C. Application of the asymmetric chelate-enolate Claisen rearrangement to the synthesis of 5-epi-isofagomine. Tetrahedron Lett. 1998, 39, 817–818. [Google Scholar] [CrossRef]
  77. Marti, C.; Carreira, E.M. Total synthesis of (-)-spirotryprostatin B: Synthesis and related studies. J. Am. Chem. Soc. 2005, 127, 11505–11515. [Google Scholar] [CrossRef]
  78. Li, P.; Xu, J.C. 1-Ethyl 2-halopyridinium salts, highly efficient coupling reagents for hindered peptide synthesis both in solution and the solid-phase. Tetrahedron 2000, 56, 8119–8131. [Google Scholar] [CrossRef]
  79. Li, P.; Xu, J.C. 2-Bromo-1-ethyl pyridinium tetrafluoroborate (BEP): A powerful coupling reagent for N-methylated peptide synthesis. Chem. Lett. 2000, 29, 204–205. [Google Scholar] [CrossRef]
  80. Barbie, P.; Kazmaier, U. Total synthesis of cyclomarins A, C and D, marine cyclic peptides with interesting anti-tuberculosis and anti-malaria activities. Org. Biomol. Chem. 2016, 14, 6036–6054. [Google Scholar] [CrossRef]
  81. Junk, L.; Papadopoulos, E.; Kazmaier, U. Tryptophan N-1-alkylation: Quick and simple access to diversely substituted tryptophans. Synthesis 2021, 53, 2503–2511. [Google Scholar] [CrossRef]
  82. Bürstner, N.; Roggo, S.; Ostermann, N.; Blank, J.; Delmas, C.; Freuler, F.; Gerhartz, B.; Hinniger, A.; Hoepfner, D.; Liechty, B.; et al. Gift from Nature: Cyclomarin A Kills Mycobacteria and Malaria Parasites by Distinct Modes of Action. ChemBioChem 2015, 16, 2433–2436. [Google Scholar] [CrossRef]
  83. Schmitt, E.K.; Riwanto, M.; Sambandamurthy, V.; Roggo, S.; Miault, C.; Zwingelstein, C.; Krastel, P.; Noble, C.; Beer, D.; Rao, S.P.S.; et al. The natural product cyclomarin kills Mycobacterium tuberculosis by targeting the ClpC1 subunit of the caseinolytic protease. Angew. Chem. Int. Ed. 2011, 50, 5889–5891. [Google Scholar] [CrossRef]
  84. Vasudevan, D.; Rao, S.P.S.; Noble, C.G. Structural basis of mycobacterial inhibition by cyclomarin A. J. Biol. Chem. 2013, 288, 30883–30891. [Google Scholar] [CrossRef][Green Version]
  85. Barbie, P.; Kazmaier, U. Total synthesis of desoxycyclomarin C and the cyclomarazines A and B. Org. Biomol. Chem. 2016, 14, 6055–6064. [Google Scholar] [CrossRef] [PubMed][Green Version]
  86. Kiefer, A.; Bader, C.D.; Held, J.; Esser, A.; Rybniker, J.; Empting, M.; Müller, R.; Kazmaier, U. Synthesis of new cyclomarin derivatives and their biological evaluation towards Mycobacterium tuberculosis and plasmodium falciparum. Chem. Eur. J. 2019, 25, 8894–8902. [Google Scholar] [CrossRef] [PubMed]
  87. Choules, M.P.; Wolf, N.M.; Lee, H.; Anderson, J.R.; Grzelak, E.M.; Wang, Y.H.; Ma, R.; Gao, W.; McAlpine, J.B.; Jin, Y.Y.; et al. Rufomycin targets ClpC1 proteolysis in Mycobacterium tuberculosis and M. abscessus. Antimicrob. Agents Chemother. 2019, 63, e02204-18. [Google Scholar] [CrossRef] [PubMed][Green Version]
  88. Nessar, R.; Cambau, E.; Reyrat, J.M.; Murray, A.; Gicquel, B. Mycobacterium abscessus: A new antibiotic nightmare. J. Antimicrob. Chemother. 2012, 67, 810–818. [Google Scholar] [CrossRef] [PubMed][Green Version]
  89. Kar, N.P.; Sikriwal, D.; Rath, P.; Choudhary, R.K.; Batra, J.K. Mycobacterium tuberculosis ClpC1. FEBS J. 2008, 275, 6149–6158. [Google Scholar] [CrossRef]
  90. Schmitz, K.R.; Sauer, R.T. Substrate delivery by the AAA+ ClpX and ClpC1 unfoldases activates the mycobacterial ClpP1P2 peptidase. Mol. Microbiol. 2014, 93, 617–628. [Google Scholar] [CrossRef][Green Version]
  91. Wolf, N.M.; Lee, H.; Choules, M.P.; Pauli, G.F.; Phansalkar, R.; Anderson, J.R.; Gao, W.; Ren, J.H.; Santarsiero, B.D.; Lee, H.; et al. High-resolution structure of CIpC1-rufomycin and ligand binding studies provide a framework to design and optimize anti-tuberculosis leads. ACS Infect. Dis. 2019, 5, 829–840. [Google Scholar] [CrossRef]
  92. Wolf, N.; Lee, H.; Choules, M.; Klein, L.; Petukhova, V.; Tufano, M.; Phansalkar, R.; Gao, W.; Santarsiero, B.; Lee, H.; et al. High-resolution structure of Clpc1-Ntd-Rufomycin complex provides three-dimensional framework for optimization of cyclopeptide anti-Tb drug leads. Protein Sci. 2018, 27, 119–120. [Google Scholar]
  93. Wolf, N.M.; Lee, H.; Nam, J.; Hong, J.; Duc, N.M.; Ho, N.A.; Lee, H.; Suh, J.W.; Pauli, G.F.; Franzblau, S.G.; et al. Structures of CIpC1-NTD with potent anti-TB cyclic peptides Rufomycin and Ecumicin: Implications for the mechanism of action and design of therapeutic agents. Acta Cryst. A 2019, 75, A59. [Google Scholar] [CrossRef]
  94. Xie, Q.; Yang, Z.J.; Huang, X.M.; Zhang, Z.K.; Li, J.B.; Ju, J.H.; Zhang, H.; Ma, J.Y. Ilamycin C induces apoptosis and inhibits migration and invasion in triple-negative breast cancer by suppressing IL-6/STAT3 pathway. J. Hematol. Oncol. 2019, 12, 60. [Google Scholar] [CrossRef] [PubMed][Green Version]
  95. Intaraudom, C.; Rachtawee, P.; Suvannakad, R.; Pittayakhajonwut, P. Antimalarial and antituberculosis substances from Streptomyces sp. BCC26924. Tetrahedron 2011, 67, 7593–7597. [Google Scholar] [CrossRef]
  96. Weinhäupl, K.; Brennich, M.; Kazmaier, U.; Lelievre, J.; Ballell, L.; Goldberg, A.; Schanda, P.; Fraga, H. The antibiotic cyclomarin blocks arginine-phosphate-induced millisecond dynamics in the N-terminal domain of ClpC1 from Mycobacterium tuberculosis. J. Biol. Chem. 2018, 293, 8379–8393. [Google Scholar] [CrossRef][Green Version]
  97. Maurer, M.; Linder, D.; Franke, K.B.; Jager, J.; Taylor, G.; Gloge, F.; Gremer, S.; Le Breton, L.; Mayer, M.P.; Weber-Ban, E.; et al. Toxic activation of an AAA plus protease by the antibacterial drug cyclomarin A. Cell Chem. Biol. 2019, 26, 1169–1179. [Google Scholar] [CrossRef] [PubMed]
Figure 1. Selected ilamycins/rufomycins and cyclomarins.
Figure 1. Selected ilamycins/rufomycins and cyclomarins.
Marinedrugs 19 00446 g001
Figure 2. Biosynthesis of rufomycins and (modified) cyclomarins; (a) Rufomycin gene cluster, (b) Cyclomarin gene cluster, (c) Metamarin gene cluster.
Figure 2. Biosynthesis of rufomycins and (modified) cyclomarins; (a) Rufomycin gene cluster, (b) Cyclomarin gene cluster, (c) Metamarin gene cluster.
Marinedrugs 19 00446 g002
Figure 3. Cyclomarazines.
Figure 3. Cyclomarazines.
Marinedrugs 19 00446 g003
Scheme 1. Retrosynthesis of ilamycins (Guo and Ye).
Scheme 1. Retrosynthesis of ilamycins (Guo and Ye).
Marinedrugs 19 00446 sch001
Scheme 2. Synthesis of peptide fragment 1.
Scheme 2. Synthesis of peptide fragment 1.
Marinedrugs 19 00446 sch002
Scheme 3. Synthesis of peptide fragment 2.
Scheme 3. Synthesis of peptide fragment 2.
Marinedrugs 19 00446 sch003
Scheme 4. Synthesis of ilamycinE1 and F.
Scheme 4. Synthesis of ilamycinE1 and F.
Marinedrugs 19 00446 sch004
Scheme 5. Synthesis of protected tryptophan 20 (building block ①).
Scheme 5. Synthesis of protected tryptophan 20 (building block ①).
Marinedrugs 19 00446 sch005
Scheme 6. Synthesis of protected hydroxyleucine 28 (building block ②).
Scheme 6. Synthesis of protected hydroxyleucine 28 (building block ②).
Marinedrugs 19 00446 sch006
Scheme 7. Synthesis of protected β-methoxy phenylalanine 32 (building block ④).
Scheme 7. Synthesis of protected β-methoxy phenylalanine 32 (building block ④).
Marinedrugs 19 00446 sch007
Scheme 8. Synthesis of protected dehydroamino acid 38 (building block ⑦).
Scheme 8. Synthesis of protected dehydroamino acid 38 (building block ⑦).
Marinedrugs 19 00446 sch008
Scheme 9. Cyclization attempts for cyclomarin C [56].
Scheme 9. Cyclization attempts for cyclomarin C [56].
Marinedrugs 19 00446 sch009
Scheme 10. Synthesis of cyclomarin C.
Scheme 10. Synthesis of cyclomarin C.
Marinedrugs 19 00446 sch010
Scheme 11. Synthesis of tryptophan derivative 59 (building block ①).
Scheme 11. Synthesis of tryptophan derivative 59 (building block ①).
Marinedrugs 19 00446 sch011
Scheme 12. Synthesis of δ-hydroxyleucine derivative 59 (building block ②).
Scheme 12. Synthesis of δ-hydroxyleucine derivative 59 (building block ②).
Marinedrugs 19 00446 sch012
Scheme 13. Synthesis of β-methoxyphenylalanine derivatives (building block ④).
Scheme 13. Synthesis of β-methoxyphenylalanine derivatives (building block ④).
Marinedrugs 19 00446 sch013
Scheme 14. Synthesis of unsaturated amino acid 69 (building block ⑦).
Scheme 14. Synthesis of unsaturated amino acid 69 (building block ⑦).
Marinedrugs 19 00446 sch014
Scheme 15. Syntheses of cyclomarin A and C.
Scheme 15. Syntheses of cyclomarin A and C.
Marinedrugs 19 00446 sch015
Scheme 16. Synthesis of cyclomarin derivatives via mutasyntheses.
Scheme 16. Synthesis of cyclomarin derivatives via mutasyntheses.
Marinedrugs 19 00446 sch016
Scheme 17. Synthesis of cyclomarin derivatives via semisyntheses.
Scheme 17. Synthesis of cyclomarin derivatives via semisyntheses.
Marinedrugs 19 00446 sch017
Figure 4. Desoxycyclomarins obtained by total syntheses.
Figure 4. Desoxycyclomarins obtained by total syntheses.
Marinedrugs 19 00446 g004
Figure 5. Most active ilamycins.
Figure 5. Most active ilamycins.
Marinedrugs 19 00446 g005
Figure 6. Most active rufomycins.
Figure 6. Most active rufomycins.
Marinedrugs 19 00446 g006
Table 1. Biological data of cyclomarins and selected desoxycyclomarins.
Table 1. Biological data of cyclomarins and selected desoxycyclomarins.
Marinedrugs 19 00446 i001
wt Erdman
Isoniazid 0.9
CQ 3.4233.9
Cyclomarin A Marinedrugs 19 00446 i002 Marinedrugs 19 00446 i003MeH0.12536.827.7
Cyclomarin C Marinedrugs 19 00446 i004 Marinedrugs 19 00446 i005MeH0.2542.8
Desoxycyclomarin C Marinedrugs 19 00446 i006 Marinedrugs 19 00446 i007MeH0.939.8
87a Marinedrugs 19 00446 i008 Marinedrugs 19 00446 i009MeH0.59.012.9
87b Marinedrugs 19 00446 i010 Marinedrugs 19 00446 i011MeH1.74.46.5
87ciPr Marinedrugs 19 00446 i012MeH0.447.876.0
87dMe Marinedrugs 19 00446 i013MeH0.913.417.8
87eH Marinedrugs 19 00446 i014MeH1.528.127.5
88aiPr Marinedrugs 19 00446 i015MeH0.4355.7300.3
88bMe Marinedrugs 19 00446 i016MeH1.6230.3256.7
88cH Marinedrugs 19 00446 i017MeH0.5314.2421.5
89a Marinedrugs 19 00446 i018 Marinedrugs 19 00446 i019HH2.347.936.7
89biPr Marinedrugs 19 00446 i020HH1.8177.5287.8
89cMe Marinedrugs 19 00446 i021HH3.4362.4318.4
90a Marinedrugs 19 00446 i022 Marinedrugs 19 00446 i023MeNH20.25
90b Marinedrugs 19 00446 i024 Marinedrugs 19 00446 i025MeN30.26
90c Marinedrugs 19 00446 i026 Marinedrugs 19 00446 i027MeNO20.13
90d Marinedrugs 19 00446 i028 Marinedrugs 19 00446 i029MeBr4.1
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Kazmaier, U.; Junk, L. Recent Developments on the Synthesis and Bioactivity of Ilamycins/Rufomycins and Cyclomarins, Marine Cyclopeptides That Demonstrate Anti-Malaria and Anti-Tuberculosis Activity. Mar. Drugs 2021, 19, 446.

AMA Style

Kazmaier U, Junk L. Recent Developments on the Synthesis and Bioactivity of Ilamycins/Rufomycins and Cyclomarins, Marine Cyclopeptides That Demonstrate Anti-Malaria and Anti-Tuberculosis Activity. Marine Drugs. 2021; 19(8):446.

Chicago/Turabian Style

Kazmaier, Uli, and Lukas Junk. 2021. "Recent Developments on the Synthesis and Bioactivity of Ilamycins/Rufomycins and Cyclomarins, Marine Cyclopeptides That Demonstrate Anti-Malaria and Anti-Tuberculosis Activity" Marine Drugs 19, no. 8: 446.

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop